Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

OBJECTIVE: We investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE. METHODS: IFNAR1 surface expression and internalisation on human monocytes before...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lupus Sci Med
Main Authors: Riggs, Jeffrey M, Hanna, Richard N, Rajan, Bhargavi, Zerrouki, Kamelia, Karnell, Jodi L, Sagar, Divya, Vainshtein, Inna, Farmer, Erika, Rosenthal, Kimberly, Morehouse, Chris, de los Reyes, Melissa, Schifferli, Kevin, Liang, Meina, Sanjuan, Miguel A, Sims, Gary P, Kolbeck, Roland
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Clinical Trials and Drug Discovery
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890856/
https://ncbi.nlm.nih.gov/pubmed/29644082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2018-000261
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados